Summit's Lead Antimicrobial Fails Pivotal Study, May Spark Therapeutic Shift
Stock Down 50%
Ridinilazole fell short of significance in a late-stage trial, with some analysts now anticipating the company will alter its therapeutic strategy entirely.
You may also be interested in...
The outcome of any clinical study is uncertain but the choice of active comparator and sometimes even the placebo arm can magnify unpredictability. Emgality’s recent head-to-head failure in migraine is just the latest in a long list of casualties.
Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.
Halfway through a race, adding more athletes, taking out some hurdles and extending the distance until the finish would be unsporting in track and field. But not in clinical trials.